Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Shattuck Labs, Inc. - Common Stock
(NQ:
STTK
)
1.250
-0.010 (-0.79%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Shattuck Labs, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
STTK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Shattuck Labs, Inc. and Encourages Investors to Contact the Firm
October 29, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
STTK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Shattuck Labs, Inc. and Encourages Investors to Contact the Firm
October 28, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 09, 2024
Via
Benzinga
Shattuck Labs Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
August 27, 2024
Via
Benzinga
Assessing Shattuck Labs: Insights From 7 Financial Analysts
August 02, 2024
Via
Benzinga
Assessing Shattuck Labs: Insights From 6 Financial Analysts
June 14, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 08, 2024
Via
Benzinga
STTK is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
October 04, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
STTK is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
October 04, 2024
NEW YORK, NY - (NewMediaWire) - October 04, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ:...
Via
TheNewswire.com
Kaplan Fox & Kilsheimer LLP is Investigating Potential Securities Law Violations Against Shattuck Labs, Inc. (STTK)
October 03, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Kaplan Fox & Kilsheimer LLP is Investigating Potential Securities Law Violations Against Shattuck Labs, Inc. (STTK)
October 03, 2024
NEW YORK, NY - (NewMediaWire) - October 03, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ:...
Via
TheNewswire.com
Kaplan Fox & Kilsheimer LLP is Investigating Shattuck Labs, Inc. (STTK) for Potential Securities Law Violations
October 02, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Kaplan Fox & Kilsheimer LLP is Investigating Shattuck Labs, Inc. (STTK) for Potential Securities Law Violations
October 02, 2024
NEW YORK, NY - (NewMediaWire) - October 02, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ:...
Via
TheNewswire.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 02, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 01, 2024
Via
Benzinga
Shattuck Labs Shutters Cancer Program, Lays Off Around 40% Of Its Workforce, Reorganizes Pipeline
October 01, 2024
Shattuck Labs shifts focus to SL-325 after modest survival improvements in a Phase 1 trial for HR-MDS and TP53m AML. The company plans workforce reductions and expects cash reserves to last into 2027.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 01, 2024
Via
Benzinga
Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway
October 01, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
STTK Stock Earnings: Shattuck Labs Misses EPS, Beats Revenue for Q2 2024
August 01, 2024
STTK stock results show that Shattuck Labs missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 01, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference
July 30, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes
July 01, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday
June 20, 2024
Via
Benzinga
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid
June 14, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)
June 10, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk
June 06, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the
May 14, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
STTK Stock Earnings: Shattuck Labs Beats EPS, Beats Revenue for Q1 2024
May 02, 2024
STTK stock results show that Shattuck Labs beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 02, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
April 09, 2024
From
Shattuck Labs, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.